SCHEMBL213401

SCHEMBL213401

O=[N+]([O-])c1cc(F)ccc1OCCN1CCOCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C19 P33261 1/20 0.65
KDM4E B2RXH2 6/20 0.60
ALDH1A1 P00352 4/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPT P10636 2/20 0.52
TDP1 Q9NUW8 1/20 0.50
GAA P10253 1/20 0.50
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
LMNA P02545 1/20 0.48
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CHEK1 O14757 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL212946 0.90 CYP1A2 (0.65) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL959211 0.89 ALDH1A1 (0.56) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL1852361 0.85 CYP2D6 (0.88) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL5692235 0.84 CYP1A2 (0.60) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
Hydrochloric Acid SCHEMBL1598446 0.83 CYP1A2 (0.59) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL25378553 0.83 CYP1A2 (0.68) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL2305590 0.82 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL4834964 0.82 ALDH1A1 (0.66) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL573096 0.81 CYP1A2 (0.56) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL1596468 0.81 ALDH1A1 (0.58) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 CYP1A2 1305/4885CYP2D6 2567/4885CYP2C19 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.